Mordecia Dickenson
Family · Bartlett, TNNPI 1629413091
Payments from drug & device makers
Across 341 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- GSK$659
- Abbott$471
- Lilly USA, LLC$458
- AstraZeneca$419
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,921100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 99 | $1,508 |
| Novo Nordisk | 52 | $1,326 |
| GSK | 41 | $659 |
| Abbott | 22 | $471 |
| Lilly USA, LLC | 22 | $458 |
| AstraZeneca | 15 | $419 |
| Bayer | 4 | $355 |
| Biohaven Pharmaceuticals, Inc. | 12 | $322 |
| Impel Pharmaceuticals Inc. | 14 | $189 |
| Boehringer Ingelheim | 7 | $186 |
| Idorsia Pharmaceuticals US Inc | 11 | $178 |
| Dexcom, Inc. | 4 | $115 |
| Redhill Biopharma Inc. | 2 | $106 |
| Kowa Pharmaceuticals America, Inc. | 3 | $60 |
| Pfizer | 4 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Inogen, Inc. | 3 | $35 |
| Eisai Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $32 |
| Exact Sciences | 2 | $32 |
| Averitas Pharma Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,921 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $108,597 |
| TrulicityDulaglutide | 27 | $49,769 |
| MounjaroTirzepatide | 39 | $42,517 |
| TradjentaLinagliptin | 30 | $35,406 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $34,457 |
| JardianceEmpagliflozin | 22 | $30,878 |
| XareltoRivaroxaban | 26 | $23,480 |
| LinzessLinaclotide | 17 | $22,178 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $20,109 |
| EliquisApixaban | 24 | $19,192 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $15,199 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $8,245 |
| Advair DiskusFluticasone Propion/Salmeterol | 16 | $5,356 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,923 |
| Pregabalin | 36 | $2,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,326 | $108,59770 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $458 | $92,28566 claims |
| Boehringer IngelheimTradjenta, Jardiance | $186 | $66,28552 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $659 | $49,65674 claims |
| Johnson & JohnsonXarelto | $18 | $23,48026 claims |
| AbbVieLinzess | $1,508 | $22,17817 claims |
| PfizerEliquis | $53 | $19,19224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Bartlett
- Stacy ScrewsBartlett$58K
- Belinda PresleyBartlett$33K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.